$CRBP

Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating

Oppenheimer has revised its price target for Corbus Pharmaceuticals (NASDAQ: CRBP) to $54, down from the previous $57, while reiterating an Outperform rating. The article, primarily a headline and a company overview, also lists several recent news items related to Corbus Pharmaceuticals from April and March 2026, including other analyst rating adjustments and clinical trial updates.

Original reporting
marketscreener.com · MT Newswires
Published May 13, 2026, 1:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 13, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CRBP
Neutral
medium confidence
Mentioned
$CRBP
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$CRBPNeutralMed
01

Why it matters

The revision indicates a tempered outlook but does not suggest a fundamental deterioration. Investors should interpret this as a cautious signal rather than a bearish one.

02

Market read

The news is relevant for biotech investors and traders focusing on CRBP, with moderate impact expected in the short term.

03

What to watch

Potential upcoming news or data releases that could positively influence the stock; broader sector recovery trends.

Timing: short to medium term (next 1-3 months)

Background

Corbus Pharmaceuticals is a biotech firm focused on inflammatory and fibrotic diseases. Oppenheimer's analyst revision reflects recent company developments and sector sentiment.

Company-level read

Ticker impact

$CRBPNeutralMedium confidence
Context

The news pertains to a price target adjustment and rating reaffirmation for Corbus Pharmaceuticals, which is relevant for traders interested in biotech and life sciences sectors.

Expected impact

Potential short-term slight decline or consolidation around current levels; long-term outlook remains cautiously optimistic.

Evidence & confidence

The price target reduction suggests some valuation correction, but the maintained Outperform rating indicates ongoing confidence. Market reaction will depend on broader sector trends and investor sentiment.

Market effects

The biotech sector may experience minor volatility; investors should monitor sector-wide news for broader trends.

Limited regional impact; primarily affecting US-based biotech stocks.

Low; this is a company-specific analyst update with minimal global market implications.

Counterpoint

The price target reduction may be overcautious; positive clinical trial updates or upcoming catalysts could lead to a rebound.

Key entities

  • Corbus Pharmaceuticals

    Biotech company specializing in inflammatory and fibrotic diseases.

  • Oppenheimer

    Investment bank providing analyst ratings and price targets.

Related articles

$CRBPMed

Corbus Pharmaceuticals Holdings, Inc. (CRBP): Results of Operations and Financial Condition

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 crbp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enr

$CRBPHighAI 9/10

Corbus Pharmaceuticals Announces Updated Data From CRB-701 Study, Stock Down In Pre-Market

Corbus Pharmaceuticals (CRBP) reported updated Phase 1/2 data for CRB-701 in 2L oropharyngeal and cervical cancers, based on an April 1, 2026 cut with 317 patients. It cited ORR of 42.9% (median DOR 6.3 months, PFS 5.6) in OPSCC and 34.4% (DOR 8.0, PFS 4.3) in cervical cancer. The company plans registrational trials starting with TEMPO-1 in summer 2026; shares were down 12.79% pre-market to $9.90.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.